• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Comment

Ambrosia Collective brings Solein-based protein to US market

By Thomas WesterholmAnalyst
Solar Foods

Translation: Original published in Finnish on 1/13/2026 at 7:42 am EET.

The companies plan to launch a protein powder made from Solein in the first quarter of 2026. While this news aligns with the company's commercialization strategy, we do not expect a single batch to have a material impact on our estimates.

New opening in sports nutrition market

Solar Foods announced on Monday that it had received an order from Ambrosia Collective, a US-based manufacturer of sports nutrition products. The collaboration aims to launch a Solein-powered ready-to-mix protein powder under the Planta brand. A limited amount of products is intended to be available for consumers during the first quarter of 2026. Ambrosia is a company focused on sports nutrition and health supplements, with a product range that includes protein supplements and wellness products.

Step in line with the strategy

This announcement is an extension of Solar Foods' strategy to commercialize Solein in the US, initially focusing on the Health & Performance nutrition market. The company announced a similar development in November, when it revealed its collaboration with Fermenta on protein bars. We view this news as a positive sign of Solein's appeal in the sports nutrition market, where consumers are often eager to try new, innovative ingredients. The United States is a key market for Solar Foods, and launches like this are important steps in raising awareness of the product.

Economic impact likely to remain minor

According to the press release, this is a limited batch, so we do not expect the order to have a significant direct impact on Solar Foods' short-term figures. In the broader context of the investment story, the focus remains on advancing and financing the industrial-scale Factory 02 project, which is a prerequisite for significant future volume growth. The news does not impact our estimates or our view of the company.

Login required

This content is only available for logged in users

Create account

Solar Foods established in 2017 is a global leader in sustainable protein production, solving the global food production problem by offering a completely new alternative to existing animal and plant proteins. Solar Foods’ first product is the naturally occurring single-cell protein Solein®, which can be used as a food raw material with high protein content. In the long run, Solein production will improve global availability of protein and increase price and quality stability of food raw materials by disconnecting food production from agriculture.

Read more on company page

Key Estimate Figures15.08.2025

202425e26e
Revenue0.00.32.1
growth-%275.5 %1,642.7 %528.4 %
EBIT (adj.)-8.9-9.5-12.1
EBIT-% (adj.)-47,635.3 %-2,913.1 %-589.3 %
EPS (adj.)-0.45-0.45-0.52
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.1,962.4neg.

Forum discussions

Here are Thomas’s comments as the Solein consumer product enters the U.S. market Solar Foods announced on Tuesday that the first consumer product...
6/3/2026, 8:18 AM
by Sijoittaja-alokas
3
Here are Thomas’s comments on Solar Foods’ partnership with Fortum Inderes – 15 May 26 Solar Foods: Fortum-kumppanuus madaltaa Factory 02:n ...
5/15/2026, 6:17 AM
by Sijoittaja-alokas
3
True, it requires documentation regarding toxicity, among other things, and that is of course how it should be. My post was partially unsuccessful...
5/9/2026, 4:43 AM
by Turska tai kuitti
1
Of course they want it and of course it has to be researched, since it is a novel food. It’s a completely standard thing.
5/9/2026, 2:51 AM
1
Did you look at the link I shared? I didn’t make up the toxicity part; EFSA wants to see documentation regarding, among other things, toxicity...
5/8/2026, 9:24 PM
by OsakasOssi
1
The word “toxicity” sounds a bit off to me, given that—at least on paper—solein is an excellent protein for human consumption (amino acids, ...
5/8/2026, 9:07 PM
by Turska tai kuitti
1
On top of this is the fact that no health authority in any significant market has yet approved the product, so the project might stall for that...
5/8/2026, 12:53 PM
by OsakasOssi
2